Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Condition Directory

Parkinson's Disease clinical trials

Directory of U.S. ClinicalTrials.gov public records for Parkinson's Disease. Browse Parkinson's Disease recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 13, 2026 Report an issue

ClinicalTrials.gov public records Last synced Oct 13, 2026, 12:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
256
Shown on this page
12
Current sort
Recently updated
Condition scope
Parkinson's Disease
Additional filters apply within this condition.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

How Parkinson's Disease studies are organized in the registry

Records generally use the registry spelling “Parkinson disease.” The portfolio mixes drug studies with a high share of device, exercise, and rehabilitation research, so the study-type filter is unusually useful here. Disease-stage language (“early,” “advanced,” “levodopa-treated”) commonly appears in titles.

Terms that often appear in related listings
early Parkinson deep brain stimulation levodopa gait

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Filter and sort this condition

These controls apply only within Parkinson's Disease. Default order is Recently updated. Add location, sponsor, treatment, or recruitment status to narrow this condition page further.

Reset condition filters
Clear filters
Showing 133–144 of 256 matching trials for Parkinson's Disease.
Live ClinicalTrials.gov results.
Active filters: "levodopa" Clear condition filters
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Completed Phase 2 Interventional

Efficacy and Safety of AFQ056 When Combined With Increased Doses of L-dopa in Parkinson's Disease Patients With Moderate-severe L-dopa Induced Dyskinesia

NCT01092065
View directory record Official record
Conditions
Parkinson's Disease
Interventions
AFQ056 with L-dopa, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
30 Years to 80 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
Sunnyvale, California • Englewood, Colorado • Indianapolis, Indiana + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2020 · Synced Oct 13, 2026, 12:47 PM EDT
Completed Phase 2 Interventional

Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

NCT01491529
View directory record Official record
Conditions
Dyskinesias, Parkinson Disease, Movement Disorders, Parkinsonian Disorders, Anti-Dyskinesia Agents
Interventions
AFQ056, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
30 Years to 80 Years
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
5
States / cities
Sunnyvale, California • Englewood, Colorado • Tampa, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2020 · Synced Oct 13, 2026, 12:47 PM EDT
Completed Phase 2 Interventional

Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

NCT01491932
View directory record Official record
Conditions
Dyskinesias, Parkinson Disease, Movement Disorders, Parkinsonian Disorders, Anti-Dyskinesia Agents
Interventions
AFQ056
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
Englewood, Colorado • Kansas City, Kansas • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 23, 2020 · Synced Oct 13, 2026, 12:47 PM EDT
Completed Phase 3 Interventional Results available

Open-Label Safety Study of ADS-5102 in PD Patients With LID

NCT02202551
View directory record Official record
Conditions
Dyskinesia, Levodopa Induced Dyskinesia (LID), Parkinson's Disease (PD)
Interventions
ADS-5102
Drug
Lead sponsor
Adamas Pharmaceuticals, Inc.
Industry
Eligibility
30 Years to 85 Years
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
54
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2020 · Synced Oct 13, 2026, 12:47 PM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease (DYSCOVER)

NCT02799381
View directory record Official record
Conditions
Parkinson's Disease (PD)
Interventions
Optimized antiparkinsonian treatment, Levodopa-Carbidopa Intestinal Gel (LCIG), CADD-Legacy ambulatory infusion pump, Percutaneous endoscopic gastrostomy tube, Jejunal extension tube
Drug · Device
Lead sponsor
AbbVie
Industry
Eligibility
30 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Port Charlotte, Florida • Round Rock, Texas
Source: ClinicalTrials.gov public record
Updated Aug 18, 2020 · Synced Oct 13, 2026, 12:47 PM EDT
Completed Phase 3 Interventional Results available

A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease (ADVANCE-PD).

NCT00974974
View directory record Official record
Conditions
Parkinson's Disease
Interventions
IPX066, IR CD-LD
Drug
Lead sponsor
Impax Laboratories, LLC
Industry
Eligibility
30 Years and older
Enrollment
471 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
35
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 30 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Oct 13, 2026, 12:47 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety and Tolerability Study of APL-130277 for the Acute Treatment of OFF Episodes in Patients With Parkinson's Disease

NCT02469090
View directory record Official record
Conditions
Parkinson Disease, Off Episodes
Interventions
APL-130277, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
32
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2020 · Synced Oct 13, 2026, 12:47 PM EDT
Completed Early Phase 1 Interventional

Improving Walking Automaticity in Parkinson's Disease: Levodopa or Donepezil

NCT03599726
View directory record Official record
Conditions
Parkinson Disease
Interventions
Donepezil, Placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
50 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 11, 2020 · Synced Oct 13, 2026, 12:47 PM EDT
Completed Phase 1 Interventional

Safety Study of AADC Gene Therapy (VY-AADC01) for Parkinson's Disease

NCT01973543
View directory record Official record
Conditions
Parkinson's Disease
Interventions
VY-AADC01
Biological
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
40 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
2
States / cities
San Francisco, California • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 3, 2020 · Synced Oct 13, 2026, 12:47 PM EDT
Completed Phase 3 Interventional Results available

Efficacy of Isradipine in Early Parkinson Disease

NCT02168842
View directory record Official record
Conditions
Parkinson Disease
Interventions
Isradipine, Placebo (for Isradipine)
Drug
Lead sponsor
University of Rochester
Other
Eligibility
30 Years and older
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
47
States / cities
Birmingham, Alabama • Sun City, Arizona • Fountain Valley, California + 40 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2020 · Synced Oct 13, 2026, 12:47 PM EDT
Completed Phase 2 Interventional Results available

High and Low Dose Carbidopa Treatment of Parkinson's Disease

NCT01399905
View directory record Official record
Conditions
Parkinson's Disease
Interventions
carbidopa
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
35 Years to 85 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 9, 2020 · Synced Oct 13, 2026, 12:47 PM EDT
Completed Phase 3 Interventional Results available

An Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects With Parkinson's Disease

NCT01096186
View directory record Official record
Conditions
Parkinson's Disease
Interventions
IPX066 95 mg, IPX066 145 mg, IPX066 195 mg, IPX066 245 mg
Drug
Lead sponsor
Impax Laboratories, LLC
Industry
Eligibility
30 Years and older
Enrollment
617 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 30 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2019 · Synced Oct 13, 2026, 12:47 PM EDT

About this Parkinson's Disease clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Parkinson's Disease as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results
Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Parkinson's Disease.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Parkinson's Disease.